A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Head and Neck Squamous Cell CarcinomaSoft Tissue Sarcoma AdultTriple Negative Breast Cancer

Interventions

DRUG

PBA-0111

Intratumoral microdose injection by the CIVO device.

Trial Locations (1)

RECRUITING

LSU Health Sciences Center, Shreveport

All Listed Sponsors

lead

Pure Biologics S.A.

INDUSTRY